These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16138006)

  • 61. Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.
    Srinivas S; Krishnan AV; Colocci N; Feldman D
    Urology; 2006 May; 67(5):1001-6. PubMed ID: 16698360
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
    Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
    Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg WD; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak DP; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small EJ; Smith MR; Trump DL; Wilding G
    J Clin Oncol; 1999 Nov; 17(11):3461-7. PubMed ID: 10550143
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
    Ryan CJ; Stadler WM; Roth B; Hutcheon D; Conry S; Puchalski T; Morris C; Small EJ
    Invest New Drugs; 2007 Oct; 25(5):445-51. PubMed ID: 17458505
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
    Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
    Shazer RL; Jain A; Galkin AV; Cinman N; Nguyen KN; Natale RB; Gross M; Green L; Bender LI; Holden S; Kaplan L; Agus DB
    BJU Int; 2006 Apr; 97(4):691-7. PubMed ID: 16536755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
    Vaishampayan U; Fontana J; Du W; Hussain M
    Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient.
    Blesa JM; Candel VA
    Onkologie; 2010; 33(1-2):57-9. PubMed ID: 20164664
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
    Mathew P; Logothetis CJ; Dieringer PY; Chen I; Pagliaro LC; Bekele BN; Zhou X; Daliani DD
    Clin Genitourin Cancer; 2006 Sep; 5(2):144-9. PubMed ID: 17026803
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
    Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
    Marsh Rde W; Rocha Lima CM; Levy DE; Mitchell EP; Rowland KM; Benson AB
    Am J Clin Oncol; 2007 Feb; 30(1):26-31. PubMed ID: 17278891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.